Focal therapy for prostate cancer can preserve potency
Nearly two-hundred-thousand American men are diagnosed with prostate cancer
each year.
And treatments like radiation and surgery often target the entire prostate, even when only part of the gland is cancerous. Aggressive treatment can result in urinary incontinence or loss of potency in some men.
But Duke University Medical Center experts say a pinpointed new surgery called focal therapy is effective in targeting only the cancerous portion of the prostate, sparing surrounding healthy tissue.
Dr. Thomas Polascik
These days theres some concern that many Americans are overtreated for prostate cancer when they may not need such aggressive treatment. So this is a way to preserve bodily functions—most notably continence and potency while attempting to control the cancer.
During focal therapy, the cancerous part of the prostate is treated with cryotherapy, which kills cancer cells by freezing them. The rest of the prostate is left untreated, preserving its function.
One of the benefits of focal therapy is that it can be repeated and what may happen in the future is we may transform prostate cancer into a chronic disease. In other words, if a patient is treated and then has a recurrence many years down the road, that treatment can be repeated.
Doctors say biopsies are periodically needed after therapy to be sure untreated sections of the prostate remain cancer-free.
A recent analysis by Duke surgeons found continence is maintained in nearly 98% of patients who receive focal therapy, and up to 90% of patients maintain potency.
About one in five patients with prostate cancer may be candidates for focal therapy. At the Duke University Medical Center, Im Mike Garrison
Duration : 0:2:14
Learn the advantages and disadvantages of this combination approach to treating men with prostate cancer spreading outside the gland
“PSA allows us to detect prostate cancer several years before that nodule would develop, at a much earlier stage, and therefore at a much more curable stage.” Drs. Schlegel (Department Chairman) and Tewari of Cornell Urology discuss the application of PSA tests, digital rectum exams, and other approaches that enable urologists to diagnose prostate cancer earlier. A family history of prostate cancer and the implications relative to a diagnosis of prostate cancer is also discussed. The need to receive a PDA and at what age is also covered by one of the leading prostate cancer researchers.
http://timdziuk.com This is an educational video for cancer patients who will
Learn more at http://www.mdanderson.org/care_centers/radiationonco/
“There’s no doubt that if the cancer is picked up early, it gives many more treatment options than if it’s picked up later.” Dr. Tewari (leader in prostate cancer research and surgery) of Cornell Urology discusses the critical importance of early detection in prostate cancer and the benefits it has for prostate cancer patients.
Following hormone therapy, the PSA may still increase. Managing this situation is very controversial. Learn about the various options and how to decide what to do.
In some men, the PSA may still rise after radiation therapy. Is this dangerous? Do all men need to be treated? Can those who are potentially in danger be identified and selectively treated. Learn the answers in the accompanying video.
Radiation therapy is part of the treatment plan for more than half of all cancer patients. In part one of this interview with Ellen Beth Levitt, radiation therapy expert William Regine covers the following topics: